Liraglutide (3.0 mg obesity dose)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LIRAGLUTIDE-OBESITY |
|---|---|
| Type | Drug |
| Aliases | Liraglutide (3.0 mg)SaxendaSaxenda (obesity dose)VictozaVictoza (T2DM 1.8 mg)Ліраглутид (3.0 мг — обезіта-доза) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 SRC-WCRF-AICR-CUP-2018 |
Drug Facts
| Class | GLP-1 receptor agonist (intermediate-acting, once-daily) |
|---|---|
| Mechanism | Human glucagon-like peptide-1 analog (97% homology) with fatty-acid sidechain conferring albumin binding and ~13-hour half-life — once-daily subcutaneous administration. Activates GLP-1 receptors in pancreas (glucose-dependent insulin secretion + glucagon suppression), GI tract (delayed gastric emptying), and CNS (hypothalamic satiety signaling, reward-circuit modulation). At obesity dose (3.0 mg/day, Saxenda), produces ~5-8% mean weight loss vs ~2-3% on placebo (SCALE trials) — lower than semaglutide 2.4 mg (~12-15%) and tirzepatide (~15-20%). Older once-daily GLP-1 RA; supplanted by once-weekly semaglutide (Wegovy) and tirzepatide (Zepbound) for most obesity indications. Obesity is associated with 13+ cancers (IARC/WCRF) — sustained weight loss is a recognized cancer-prevention intervention pathway. |
| Typical dosing | Obesity (Saxenda) — SC dose escalation over 5 weeks: Week 1: 0.6 mg SC daily Week 2: 1.2 mg SC daily Week 3: 1.8 mg SC daily Week 4: 2.4 mg SC daily Week 5 onward: 3.0 mg SC daily (maintenance) Inject SC abdomen / thigh / upper arm at any consistent time of day; rotate sites. Discontinue if ≥4% weight loss not achieved at 16 weeks. T2DM (Victoza): 0.6 mg/day × 1 week, then 1.2 mg/day; up to 1.8 mg/day. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Warnings
- Risk of thyroid C-cell tumors — rodent carcinogenicity studies showed dose-dependent MTC and C-cell hyperplasia; human relevance unknown but precautionary contraindication for MTC/MEN2
Notes
STUB — v0.2 prevention-workstream authoring (batch 3); pending two- Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. CLASS-DETAIL entity for the GLP-1 receptor agonist class (alongside DRUG-SEMAGLUTIDE-2-4MG and DRUG-TIRZEPATIDE — note tirzepatide is technically dual GIP/GLP-1). Older once-daily GLP-1 RA (Saxenda obesity indication, Victoza T2DM indication); largely supplanted by once-weekly semaglutide (Wegovy / Ozempic) and tirzepatide (Zepbound / Mounjaro) for obesity and most T2DM indications due to greater efficacy and weekly-dosing convenience. Retains role in: pediatric obesity (FDA-approved ≥12 y with obesity), T2DM patients intolerant of weekly injections, situations where injection-discontinuation flexibility matters. Cancer-prevention rationale is class-wide (sustained 5-8% weight loss reduces obesity- driven carcinogenesis incidence per IARC/WCRF). Source cited (SRC-WCRF-AICR-CUP-2018) is the umbrella obesity-cancer evidence base until USPSTF/AACE obesity-pharmacotherapy sources land.
Used By
No reverse references found in the YAML corpus.